Healthcare · Life Sciences

Clinical-grade research on a launch timeline.

HCP, payer, and patient evidence. AI-moderated depth, researcher-led rigor.

Talk to our team
Diagnostics Strategy
Prepared for · Strategy team
NGS Oncology IVD Market Assessment
78%
Academic labs would displace their current assay
5
Countries fielded in local language
Academic78
Reference64
Community41
“If reimbursement holds, this replaces our current assay.”MOLECULAR PATHOLOGIST · ACADEMIC CENTER · INT_022
What we do

Research for every decision in the product lifecycle.

PharmaCHECKPOINT BACKBONE SELECTIONFor
2 endpoints

decide backbone preference. The KOL map reshaped the development sequence.

One hundred ten oncologists mapped on endpoint weighting: which trial readouts actually move backbone preference.

N=11014 days in fieldQuant + qual · one instrumentRead the case study →

Other research we run

Stage 01Market & landscape
  • Market landscape, sizing & forecast
  • Patient flow & line of therapy
  • Segmentation & personas
  • KOL mapping & influencer networks
  • Competitive landscape
  • Uptake & scenario modeling
Stage 02Product & positioning
  • Concept screening & message testing
  • TPP optimization & trade-offs
  • Claims & creative testing
  • Usability & workflow fit
  • Prototype & UX testing
  • Content comprehension
Stage 03Pricing & access
  • Pricing: Van Westendorp & elasticity
  • Payer access & formulary
  • Journey mapping: patient, HCP, payer
  • Referral & access pathways
  • Choice drivers & win–loss
  • Key-driver modeling
Stage 04In-market & tracking
  • Voice of customer & satisfaction
  • NPS driver analysis
  • Trackers, pulse checks & panels
  • Advisory boards
  • Longitudinal diaries & communities
  • Quick-turn ad hoc studies

AI-moderated interviews, mixed-method designs (quant + qual). If your team needs it, we field it.

Talk to our team
How it works

AI scale, human expertise.

Two weeks from final study design to delivered report. A senior researcher helps design the study, rules on every quality flag, and curates the final story. The agents handle everything in between.

NGS Oncology IVD Market AssessmentChris L. · Senior ResearcherReviewing every question
Activity log · design agent
09:41AI

Parsed the brief → 4 decision questions the study must answer

09:58RES

Researcher reframed question 2 to "displacement intent" over "interest"

10:14AI

Screener drafted: 6 criteria, specialty + case volume verified

11:02RES

Researcher tightened the screener, excluding industry consultants

11:37AI

Survey programmed · branch logic set · logic check 47/47 passed

12:05RES

Researcher ran the full survey twice. Timing, tone, and flow approved

Survey blueprint · programming in order
ScreenerQ01–Q06 · specialty + case volume
QueuedProgrammingPassed
S1 · Testing landscapeQ07–Q13
QueuedProgrammingPassed
S2 · Assay landscapeQ14–Q22 · share of walletRes edit
QueuedProgrammingPassed
S3A · Payer branchQ23–Q30 · skip logic
QueuedProgrammingPassed
S3B · Provider branchQ23–Q30 · skip logic
QueuedProgrammingPassed
S4 · Pricing elasticityQ31–Q47 · Gabor-GrangerRes edit
QueuedProgrammingPassed
Programming Q06/47Q13/47Q22/47Q38/47Logic check 47/47 passed

Design Finalization. Your researcher walks you through the study, takes your edits, and finalizes the guide. Nothing fields without researcher approval.

Human gate 1 of 3
Selected work

Research that moved
the program.

Every engagement below delivered to an insights team in days, not months.

DiagnosticsMarket SegmentationN=103
Clinical Cell Analysis Platform Segmentation
Three behavioral segments, one clear target, and a firmographic model the data overturned.
21 days→
Digital HealthPerformance ImprovementN=151
Performance Improvement Platform Validation
A vast majority see value. Buying group is collaborative, price lands within a well-defined band, timeline is 6 to 18 months.
→
DiagnosticsInflammation TestingN=84
Inflammation Testing Market Entry
Does a mature two-marker inflammation testing category hold enough unmet need to justify platform entry?
→
Life Science ToolsCrop GenomicsN=42
Agricultural Reagent Supplier Selection
Plant-specific labeling matters less than expected. Validation, documentation, and technical partnership decide the deal.
→
PharmaBrand PerceptionN=45
Clinical CRO Brand Perception
Where is a global CRO's brand earned, where is it exposed, and does the answer change across buyer segments and functions?
→
Digital HealthReal-World EvidenceN=76
Oncology RWE Market Landscape
How durable is the incumbents' hold on oncology real-world evidence, and do buyers reward the data assets a new entrant from the pharmaceutical services value chain could uniquely supply?
→
View all research →
How it compares

One partner replaces the research stack.

Most diligence research runs through strategy consultancies and traditional research agencies. The economics are public, and they are not close.

UserCueAI-scaled · researcher-led
Strategy consultanciesCommercial research workstreams
Traditional researchTier-1 agencies
Speed · stage by stage
Study design & programming
1–3 days
1–2 weeksest.
1–3 weeksest.
Fielding & QC
3–6 days
2–4 weeksest.
3–5 weeksest.
Analysis & reporting
1–3 days
1–2 weeksest.
2–4 weeksest.
Speed · total
Time to final report
10–14 daysfrom final study design
4–8 weeks
6–12 weeks
Cost
Cost per expert interview
Included in every study
$1,000–$2,000 per expert-network call
Panel CPI covers data collection only · HCP panels $80–$300+/complete
Method & rigor
Qual depth + quant scale in one study
✓One instrument, every study
◐Primarily qualitative calls
◐Usually qual or quant, rarely both
Interviews run in parallel, 24/7
✓50–1,000+ per study
✕Sequential calendars
✕Field windows
Senior researcher on every study
✓No junior handoffs
✓Partner + case team
◐Typically manager + analysts
Live QC during fielding
✓AI flags + researcher rulings
✕Post-hoc
✕Post-hoc
What ships
Deliverables
Exec summary + top-line analysis · question-by-question PDF · crosstab workbook · raw data + verbatimsdouble-blind · pseudonymized
Slide deck
Report; data files vary

One conversation replaces a procurement cycle with two vendors. The fastest way to see the fit is a 30-minute call.

Schedule a 30-minute call
What clients say
“The depth of clinical insight was exceptional. What would have taken our team months to piece together from multiple vendors arrived in ten days, with the rigor we needed to present to our medical advisory board.”VP, Global Insights · Top-20 pharma · Oncology commercial strategy

Ready to accelerate your
research timeline?

30 minutes. No pitch deck. We’ll walk through a real deliverable from your therapeutic area and show you exactly how we’d approach your next study.

Talk to our teamView HCLS case studies